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Peritoneal and hemodialysis: II. Mortality risk associated with sis (HD). The results include (1) no differences in mortal-
initial patient characteristics. ity risks between PD and HD [1–7], (2) PD having a
Background. Patients initiating with peritoneal dialysis (PD) lower risk than HD [8, 9], and (3) PD having a higherhave favorable clinical conditions compared with hemodialysis
risk than HD [10–12]. Diabetic PD patients have been(HD) patients, which may contribute to the varying results
reported in one study as having a lower risk of mortalityfound in studies of mortality across the two therapies.
Methods. National incidence data of end-stage renal disease [13] and in another as having a higher risk [14] compared
patients from 1995 to 1997 were used, excluding the first 90 with their counterparts on HD, while neither study found
days of treatment and including all patients who were on either a difference in mortality between non-diabetic PD and
PD or HD on day 91. Patients were then followed for a one-
HD patients.year period. A Cox proportional hazards regression analysis
The inconsistent results reported by these observa-was used, separating diabetics and non-diabetics, and two statis-
tical models were applied. Model 1 included race, gender, age, tional studies may be related to the unequally distributed
initial modality, and incidence year as explanatory variables. clinical conditions of patients at the initiation of dialysis,
Model 2 added body mass index (BMI), initial levels of serum as well as to the use of different patient cohorts (inci-
albumin, creatinine, and blood urea nitrogen. dence vs. prevalence). Our companion study evaluatedResults. Age was most highly associated with mortality, fol-
the clinical conditions of PD and HD patients at thelowed by biochemical variables, BMI, gender, and dialysis
initiation of dialysis (Xue et al: Peritoneal and hemodial-modality. In diabetics, the hazard ratio (HR) from Model 1
indicated no difference [1.046, 95% confidence limits (CL) ysis: I. Differences in patient characteristics at initiation,
0.989–1.105; P  0.1, HD was the reference] in mortality be- this issue of Kidney International). We found that pa-
tween PD and HD, while Model 2 demonstrated that PD pa- tients on PD were on average six years younger than
tients had a 13.4% (1.134, CL 1.072–1.100, P  0.0001) higher
those on HD, and that underweight patients had a lowerchance of death. In non-diabetics, hazard ratios (HRs) from
chance of initiating on PD compared to those of appro-Models 1 and 2 indicated that PD patients had a 23.5% (0.765,
0.722–0.812, P  0.0001) and 11.9% (0.881, 0.30–0.935, P  priate weight. In addition, PD patients had higher initial
0.0001), respectively, lower likelihood of death than HD pa- serum albumin and hematocrit levels and lower initial
tients. serum creatinine and blood urea nitrogen levels than
Conclusion. Our study indicates that the results changed HD patients. These clinical conditions at initiation maydepending on the analytical methods used. We recommend
influence comparisons of mortality outcomes betweenthat, due to the unequally distributed clinical conditions of
the therapies.patients at initiation, comparisons of mortality outcomes be-
tween dialysis modalities should be made with caution. The objective of this study was to determine the associ-
ation of clinical characteristics at the initiation of PD
and HD with one-year mortality outcomes. We used two
statistical models, one including race, gender, age, andA wide variation in mortality outcomes has been re-
incidence year as explanatory variables, and the otherported between peritoneal dialysis (PD) and hemodialy-
adding body mass index along with levels of serum albu-
min, creatinine, and blood urea nitrogen.
Key words: end-stage renal disease, mortality analysis, statistical mod-
els, dialysis modality, uremia, analysis of data.
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Table 1. First-year crude death rate by modality, race, gender, and diabetic status
Diabetics Non-diabetics
PD HD PD HD
Race Gender N patients Death % N patients Death % N patients Death % N patients Death %
White Male 3,083 20.76 13,911 24.52 3,587 17.84 20,874 24.94
Female 2,540 24.49 13,562 24.79 2,721 14.33 14,130 25.38
Black Male 635 10.87 5,743 16.44 972 12.04 10,647 16.50
Female 875 17.71 8,784 17.25 1,002 10.08 9,011 17.68
disease (ESRD) from 1995 to 1997, and determined pa- ables we then forced other variables, commonly used in
tient Medicare eligibility from the HCFA enrollment the comparison of mortality outcomes between PD and
database. In-center HD patients who are at least 65 years HD in published studies, into the final model, even
old, medically disabled, or have railroad retirement in- though some of them were not selected in the model
surance receive Medicare entitlement from the first day building process.
of ESRD onset, while in-center HD patients not meeting Two models were applied. Explanatory variables con-
any of these criteria must wait 90 days for Medicare sidered for Model 1 were incidence year, race, gender,
eligibility. Home dialysis patients, by contrast, whether age, and dialysis therapy (PD or HD). Model 2 included
on HD or PD (CAPD and CCPD), are eligible for Medi- all variables in Model 1 plus body mass index (BMI),
care reimbursement from the first day of ESRD. Because serum albumin, creatinine, and blood urea nitrogen
these rules create differences in the availability of patient (BUN) at initiation. Incidence years included 1995, 1996,
information, and in order to have complete data for both and 1997, with 1995 as reference. Race included whites
in-center and home dialysis patients, the first 90 days of and blacks (reference). Female was the reference for
treatment were excluded, including only dialysis patients gender. Age was grouped into four categories: 20–44
alive on day 91 [15]. Patients with transplants on day (reference), 45–64, 65–74, and 75. Body mass index
91, then, were excluded. We evaluated 112,077 patients: was categorized into four groups: 19, 19–25 (25),
13.75% (N  15,415) on PD, and 86.25% (N  96,662) 25–30 (30), and 30—underweight, appropriate weight,
on HD. overweight, and obesity, respectively—with BMI 19–25
To address concerns related to the case-mix of diabet- as the reference. Serum albumin, creatinine, and BUN
ics and non-diabetics [16–18], these groups of patients were treated as continuous variables. Hazard ratios (HR)
were separated in our analysis. Modality was defined as and their 95% confidence limits (CL) were determined
the dialysis therapy on day 91, regardless of later changes from the model.
in treatment. Survival time was measured by the number
of days from day 91 on dialysis, and patients were fol-
RESULTSlowed for a one-year (365 days) period. Those who sur-
Whites of both genders had higher crude death ratesvived to the end of follow-up period were censored.
than blacks regardless of diabetic status (Table 1), whileDescriptive statistics for crude death rates were calcu-
HD patients had higher rates than those on PD acrosslated by modality, race, and gender.
all race and gender groups except for diabetic white
Statistical analysis females, for whom rates were similar in both modalities.
In the stepwise selection process, Model 1 stoppedA Cox proportional hazards regression analysis was
carried out using PROC PHREG in SAS (SAS Inc., with four variables in diabetics and five in non-diabetics
(Table 2). Modality, gender, and year (1996 and 1997)Cary, NC, USA) [19, 20]. A stepwise method was first
conducted for model building, which selects explanatory were not selected in the diabetic analyses, and gender
and year (1996 and 1997) were not selected in the non-variables. The threshold for significance was 0.05 (the
default in SAS), that is, any variables associated with diabetic analyses. Model 2 stopped with 12 and 13 vari-
ables in diabetics and non-diabetics, respectively (Tabledeath at the level of P  0.05 were selected, with the
most significant variable first, the second most significant 2). Age was selected first in both models regardless of
diabetic status (Table 2). In Model 2, biochemical andvariable second, and so on. This method allows variables
previously selected to be removed from the model if BMI variables were selected following age in both dia-
betics and non-diabetics, and race, gender, and modalitythey are no longer significant after other variables are
selected. The model building process stops when all of were selected last. No variable that was previously se-
lected was removed from the models.the variables not in the model have P-values exceeding
the threshold. To determine the associations among vari- In both models and regardless of diabetic status, white
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Table 2. Orders of variables entering into the models
with the stepwise method
Diabetics Non-diabetics
Order Model 1 Model 2 Model 1 Model 2
1 Age 75 Age 75 Age 75 Age 75
2 Age 65–74 Creatinine Age 65–74 Age 65–74
3 Race BUN Age 45–64 Albumin
4 Age 45–64 Age 65–74 PD-HD Creatinine
5 Albumin Race BUN
6 BMI 19 BMI 19
7 Race Age 45–64
8 Age 45–64 BMI 30
9 BMI 30 BMI 25–30
Fig. 2. Hazard ratios for mortality of males versus females (females10 BMI 25–30 Gender
were the reference, HR  1.0), from the two statistical models. Model11 PD-HD PD-HD
1 () adjusted for race, age, dialysis modality, and incidence year.12 Gender Race
Model 2 () adjusted for body mass index and initial levels of albumin,13 Year 97
BUN, and creatinine, as well as for race, age, modality, and incidence
All variables entered into the models with the stepwise method were statisti- year. Lines at the top of bars indicate the range of 95% confidence
cally significant at P  0.05. limits of hazard ratios.
mortality (Fig. 3). For diabetics in Model 1, using age
20–44 (HR  1.0) as the reference group, the HR was
1.577 (1.447–1.719, P  0.0001) for age 45–64, 2.543
(2.334–2.771, P  0.0001) for age 65–74, and 3.992
(3.655–4.360, P  0.0001) for age 75. Hazard ratios in
non-diabetics were 1.457 (1.355–1.568, P 0.0001), 2.887
(2.694–3.093, P  0.0001), and 4.496 (4.205–4.808, P 
0.0001) for the same age groups. Hazard ratios for the
older age groups in Model 2 were similar to those in
Model 1, with lower magnitudes in both diabetics and
non-diabetics.Fig. 1. Hazard ratios for mortality of whites versus blacks (blacks were
In a comparison between dialysis modalities the mag-the reference, HR  1.0), from the two statistical models. Model 1 ()
adjusted for gender, age, dialysis modality, and incidence year. Model nitude of the HR differed with the model used (Fig. 4).
2 () adjusted for body mass index and initial levels of albumin, blood In diabetics, Model 1 indicated no difference in mortalityurea nitrogen (BUN), and creatinine, as well as for gender, age, mod-
between PD and HD (1.046, 0.989–1.105, P 0.1), whileality, and incidence year. Lines at the top of bars indicate the range of
95% confidence limits of hazard ratios. Model 2 demonstrated that patients on PD had a 13.4%
(1.134, 1.072–1.199, P  0001) higher chance of death
than those on HD (HD was reference, HR  1.0). The
difference in the comparison of mortality between PDpatients had a higher likelihood of death than black
and HD in the two models was approximately 9%. Inpatients (blacks were reference, HR  1.0; Fig. 1). In
non-diabetics, Model 1 indicated that PD patients hadModel 1 for diabetics, whites had a 45.4% (HR 1.454,
a 23.5% (0.765, 0.722–0.812, P 0.0001) lower likelihood95% CL 1.391–1.520, P 0.0001) higher chance of death,
of death than those on HD, while in Model 2 PD patientswhile the risk for non-diabetic whites was 12.2% (1.122,
had an 11.9% (0.881, 0.830–0.935, P  0.0001) lower1.078–1.168, P  0.0001) higher. When BMI and bio-
risk. The difference in reduced likelihood of mortalitychemical data were considered in Model 2, the HR of
for PD versus HD between the two models was approxi-whites versus blacks was reduced in both diabetics (1.234,
mately 12%.1.179–1.291, P 0.0001) and non-diabetics (1.052, 1.009–
Body mass index was associated with mortality (Fig.1.095, P  0.016; Fig. 1).
5). In diabetics and non-diabetics, underweight patientsNo difference in mortality between genders was ob-
(BMI19) had a 39.7% (1.397, 1.296–1.506, P 0.0001)served in diabetics (1.004, 0.966–1.043, P  0.8) or non-
and 28.5% (1.285, 1.225–1.349, P 0.0001) higher likeli-diabetics (1.031, 0.997–1.068, P  0.07) with Model 1
hood of death than those with appropriate weight (BMI(Fig. 2). With Model 2, the HR of males versus females
19–25 was reference, HR  1.0). Overweight (BMI 25–(females were reference, HR  1.0) was higher in both
30) and obese (BMI 30) patients had lower risks ofdiabetics (1.082, 1.040–1.126, P  0.0001) and non-dia-
death compared with patients of appropriate weight inbetics (1.115, 1.077–1.155, P  0.0001).
Older patients were associated with a higher risk of both diabetics (0.849, 0.811–0.890, P  0.0001 for BMI
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Fig. 3. Hazard ratios for mortality by age
(age 20–44 was the reference, HR 1.0), from
the two statistical models. Model 1 () ad-
justed for race, gender, dialysis modality, and
incidence year. Model 2 () adjusted for body
mass index and initial levels of albumin, BUN,
and creatinine, as well as for race, gender,
modality, and incidence year. Lines at the top
of bars indicate the range of 95% confidence
limits of hazard ratios.
Fig. 6. Hazard ratios for mortality by biochemical indicators (treated
as continuous variables) from Model 2, which adjusted for race, gender,
age, incidence year, and body mass index. Lines at the top of bars
Fig. 4. Hazard ratios for mortality of PD versus HD (HD was the indicate the range of 95% confidence limits of hazard ratios. Symbols
reference, HR  1.0), from the two statistical models. Model 1 () are: () diabetes; () non-diabetes.
adjusted for race, gender, age, and incidence year. Model 2 () adjusted
for body mass index and initial levels of albumin, BUN, and creatinine,
as well as for race, gender, age, and incidence year. Lines at the top of 25–30 and 0.794, 0.754–0.836, P  0.0001 for BMI 30)
the bars indicate the range of 95% confidence limits of hazard ratios. and non-diabetics (0.845, 0.809–0.883, P  0.0001 for
BMI 25–30 and 0.760, 0.715–0.807, P  0.0001 for BMI
30).
Albumin, creatinine, and BUN were also associated
with mortality (Fig. 6). In diabetics, an increase of 1 g/dL
of albumin at the initiation of dialysis was associated
with a 26.1% (0.739, 0.716–0.762, P  0.0001) lower risk
of death. In non-diabetics, the risk was reduced by 34.6%
(0.654, 0.638–0.671, P 0.0001). An increase of 1 mg/dL
in creatinine was associated with a decreased risk of
11.0% (0.890, 0.882–0.898, P  0.0001) and 6.8% (0.932,
0.926–0.938, P  0.0001) in diabetics and non-diabetics,
respectively. And for BUN, an increase of 1 mg/dL was
associated with an increased risk of 0.6% (1.006, 1.006–
1.007, P  0.0001) and 0.4% (1.004, 1.003–1.004, P 
0.0001) in diabetics and non-diabetics, respectively.
Fig. 5. Hazard ratios for mortality by body mass index (BMI 19–25
was the reference; HR  1.0) from Model 2, which adjusted for race,
gender, age, incidence year, and initial levels of albumin, BUN, and DISCUSSION
creatinine. Lines at the top of the bars indicate the range of 95%
Our primary finding in this study was that varying risksconfidence limits of hazard ratios. Symbols are: () diabetes; () non-
diabetes. of mortality between PD and HD occur when the data
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are analyzed using two different statistical models. Ac- this case, is PD better than HD, is HD better than PD,
or is there no difference in patient risk between the twocording to Model 1, the risk of first-year mortality was
less for non-diabetics on PD than for those on HD, and therapies? If the unequally distributed clinical conditions
of patients at initiation between the two dialysis thera-the same for diabetics on either modality. In Model 2,
which included biochemical and BMI data, the risk was pies are not considered, results from statistical analyses
of these therapies must themselves be skewed. As Nolphagain less for non-diabetics on PD, but diabetic PD pa-
tients had a higher risk of mortality than diabetic patients pointed out, mortality comparisons between PD and HD
should be viewed with caution since other unmeasuredon HD. While the two models both showed that PD was
associated with lower risks than HD for non-diabetics, factors may not be distributed evenly between the two
modalities [30]. Therefore, it is easy to understand whythe magnitude of the difference changed from 23.5%
with Model 1 to 11.9% with Model 2. results from comparisons of mortality outcomes between
PD and HD have been so inconsistent.It is clear that the differences found in estimated haz-
ard ratios between the modalities are not related to the Although comorbidity was associated with dialysis
modalities and with mortality [31], we did not includetherapies themselves, but are instead determined by the
variables included in the models. This can be explained co-morbid conditions, with the exception of diabetes,
recorded on the Medical Evidence Form because weby the unequally distributed clinical conditions of pa-
tients at the initiation of dialysis, and the fact that PD found that they did not closely match those recorded in
HCFA Medicare claims [abstract; Xue JL, Perit Dial Intpatients have favorable clinical conditions as indicated
by biochemical and BMI data (Xue et al, this issue). 21(Suppl 1):S84, 2001]. The same findings were reported
from the CHOICE Study using medical records [32]. WeBecause complex factors such as patient choice, comor-
bidity, vascular access failure, and the payment system believe, however, that while BMI and biochemical data
cannot replace comorbid conditions in an analysis, theyinfluence the initial assignment of patients to a modality,
there is little likelihood of randomness in that assign- are highly associated with comorbid conditions at initia-
tion.ment. One common way to adjust for the effects of fac-
tors that are not equally presented in various groups is We used the intent-to-treat method, in which modality
changes following initial therapies are not considered.to include these factors in the statistical model. When
Model 2 was used to consider clinical characteristics (bio- The hazard ratio for death of PD versus HD may shift
when data on these changes are considered [33]. Anotherchemical and BMI data) at initiation, PD appeared to
be a riskier modality compared to HD than it did in limitation of this study is that our follow-up time was
only one year. Fenton et al [8] and Collins et al [9] bothModel 1 when these characteristics were not considered.
Our model selection processes suggest that albumin, have reported higher risks of death for HD patients in
the first year, and shown that PD mortality rates appearcreatinine, BUN, and BMI were more significantly asso-
ciated with death than race, gender, and dialysis mod- to change over time.
Time frame and sample size also should be considered.ality. Many studies have demonstrated that serum albu-
min is positively correlated with dialysis survival [21]. Because patients whose dialysis type was classified as
“other” on the Medical Evidence Form were recordedWhile Fink et al reported that the level of BUN at initia-
tion had little association with dialysis outcomes [22], as being on either PD or HD by day 91 of dialysis, there
were approximately 5.8% more patients in this mortalityother studies support our findings [18, 21, 23, 24]. The
positive association we found between BUN and mortal- study than in the study of patients’ clinical characteristics
at initiation (Xue et al, this issue). To address this di-ity suggests that patients with high BUN levels at initia-
tion start dialysis at a relatively late stage of renal disease lemma, we ran the analysis without excluding the first
90 days, that is, from the first ESRD service date, and[25, 26].
An inverse relationship between creatinine levels and while slight changes in hazard ratios were found, there
was no statistical difference in the overall results.mortality has been previously reported [22, 27–29] that
appears contrary to the expectation, described by Fink In conclusion, the unequally distributed clinical condi-
tions of patients at initiation, with patients on PD havingand colleagues [22], that the creatinine levels recorded
on the Medical Evidence Form are an indicator of resid- more favorable clinical conditions than those on HD,
should be considered in the comparison of dialysis out-ual renal function at the initiation of dialysis. Lower
initial serum creatinine in underweight patients relative comes. These outcomes change significantly when factors
that are unequally distributed between the therapies areto others observed in this study (data not presented)
suggests that low levels of creatinine instead indicate included in the analysis.
loss of muscle mass due to the chronic malnutrition asso-
ciated with poor control of uremia. ACKNOWLEDGMENTS
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